



RECEIPT
#10
PATENT
Docket No: 2283/301
TECH CENTER 1600
APR 3 2001
1643/2000
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Leivan DeVeylder et al)
Serial No. : 09/574,735)
Filed : May 18, 2000)
For : CYCLIN-DEPENDENT KINASE INHIBITORS)
AND USES THEREOF)

)
Examiner:
Unknown
)
Art Unit:
1643
)

REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Dear Sir:

Applicants hereby request a corrected filing receipt for the above-identified application. There has been a **change in the attorney's name and correspondence address** for the above-identified application. Please correct the correspondence address to read as follows:

Ann R. Pokalsky
Nixon Peabody LLP
990 Stewart Avenue
Garden City, New York 11530-4838


A copy of the Notice Regarding Power of Attorney as filed on October 23, 2000 accepting this correspondence address is enclosed herewith.

In addition, on the enclosed copy of the official filing receipt, under Attorney Docket No. it should read 2283/301 and under Foreign Applications it should read "PCT/EP98/05895 09/16/1998".

Since Applicants are not responsible for this error, no fee is enclosed.

A duplicate copy of this sheet is enclosed.

Respectfully submitted,


Ann R. Pokalsky
Registration No. 34,697

Dated: January 19, 2001

Nixon Peabody LLP
990 Stewart Avenue
Garden City, New York 11530-4838
Telephone: (516) 832-7572
Facsimile: (516) 832-7555

ARP/mm

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

I certify that the attached correspondence is being deposited
on 1/19/01 with the U.S. Postal Service as first class mail
under 37 C.F.R. § 1.8 and addressed to:

Assistant Commissioner for Patents, Washington, D.C. 20231.

*Office of Initial Patent Examination
Customer Service Center* Maria I. Matos
Maria I. Matos



O I P E
JAN 22 2001
PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

TECH CENTER
A
C
S
20290

RECEIVED
A
M
3/30/01

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
09/574,735	05/18/2000	Lieven DeVeylder	135985 2000/3/30/01



OC000000005574938

Ann R. Pokalsky, Esq.
NIXON PEABODY LLP
990 Stewart Avenue
Garden City, NY 11530-4838

Date Mailed: 11/24/2000

NOTICE REGARDING POWER OF ATTORNEY

This is in response to the Power of Attorney filed 10/23/2000.


The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

Yakov Liss
Customer Service Center

Initial Patent Examination Division (703) 308-1202

ATTORNEY/APPLICANT COPY

NOV 27 2000

Recd
11/30/02

UNITED STATES PATENT AND TRADEMARK OFFICE

TECH C
A
R
E
D
COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON D.C. 20591
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/574,735	05/18/2000	1643	2589	43594Z 134237 2083/301	12	59 02900	26

Scully Scott Murphy & Presser
400 Garden City Plaza
Garden City, NY 11530

Ann R. Pokalsky, Esq.
NIXON PEABODY LLP
990 Stewart Avenue

Garden City, New York 11530

Date Mailed: 09/25/2000

FILING RECEIPT



OC00000005422408

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Lieven DeVeylder, Drongen, BELGIUM;
Tom Beeckman, Merelbeke, BELGIUM;
Dirk Inze, Moorsel-Aalst, BELGIUM;
Wim Van Camp, Sint-Denijs-Westrem, BELGIUM;
Luc Kroes, Kapellen, BELGIUM;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/526,597 03/16/2000

Foreign Applications

PCT/EP98/05895 09/16/1998
EUROPEAN PATENT OFFICE (EPO) 97 204 111.5 12/24/1997
EUROPEAN PATENT OFFICE (EPO) 97 202 838.5 09/16/1997

If Required, Foreign Filing License Granted 08/03/2000

** SMALL ENTITY **

Title

'Cyclin-dependent kinase inhibitors and uses thereof'

Preliminary Class

435

Data entry by : DELOATCH, PHYLLIS

Team : OIPE

Dat : 09/25/2000



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
 Office of Initial Patent Examination
 Customer Service Center
 Washington, DC 20231

FILE COPY**UNITED STATES PATENT AND TRADEMARK OFFICE**

COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
www.uspto.gov

**CONFIRMATION NO. 1507**

Bib Data Sheet

SERIAL NUMBER 09/574,735	FILING DATE 05/18/2000 RULE	CLASS 435	GROUP ART UNIT 1643 1638	ATTORNEY DOCKET NO. 2283/301
-----------------------------	-----------------------------------	--------------	--------------------------------	---------------------------------

APPLICANTS

Lieven DeVeylder, Drongen, BELGIUM;
 Tom Beeckman, Merelbeke, BELGIUM;
 Dirk Inze, Moorsel-Aalst, BELGIUM;
 Wim Van Camp, Sint-Denijs-Westrem, BELGIUM;
 Luc Kroels, Kapellen, BELGIUM;

**** CONTINUING DATA *******THIS APPLICATION IS A CIP OF 09/526,597 03/16/2000 *cc***** FOREIGN APPLICATIONS *******

PCT/EP98/05895 09/16/1998
 EUROPEAN PATENT OFFICE (EPO) 97 204 111.5 12/24/1997
 EUROPEAN PATENT OFFICE (EPO) 97 202 838.5 09/16/1997

**IF REQUIRED, FOREIGN FILING LICENSE
GRANTED ** 08/03/2000**

**** SMALL ENTITY ****

Foreign Priority claimed	<input checked="" type="checkbox"/> yes <input type="checkbox"/> no	STATE OR COUNTRY BELGIUM	SHEETS DRAWING 12	TOTAL CLAIMS 59	INDEPENDENT CLAIMS 26
35 USC 119 (a-d) conditions met	<input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance <i>cc</i>				
Verified and Acknowledged	Examiner's Signature <i>cc</i> Initials				

ADDRESS

Ann R. Pokalsky, Esq.
 NIXON PEABODY LLP
 990 Stewart Avenue
 Garden City ,NY 11530-4838

TITLE

Cyclin-dependent kinase inhibitors and uses thereof

FILING FEE RECEIVED 2589	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing)
		<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
		<input type="checkbox"/> 1.18 Fees (Issue)
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit

BEST AVAILABLE COPY